Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asfar S Azmi

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
Oncotargets and Therapy|February 14, 2014
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancerMarwan Al-Hajeili, Asfar S Azmi, Minsig Choi
Cancers|May 9, 2018
Nuclear Export Inhibition for Pancreatic Cancer TherapyIrfana Muqbil, Asfar S Azmi, Ramzi M Mohammad
Drug Discovery Today|June 23, 2020
Exportin 1 inhibition as antiviral therapyMd Hafiz Uddin, Jeffrey A Zonder, Asfar S Azmi
Nature Reviews. Clinical Oncology|November 11, 2020
The nuclear export protein XPO1 - from biology to targeted therapyAsfar S Azmi, Mohammed H Uddin, Ramzi M Mohammad
Frontiers in Oncology|December 19, 2022
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Sahar F Bannoura, Husain Yar Khan, Asfar S Azmi
Clinical and Translational Medicine|February 2, 2013
Network insights on oxaliplatin anti-cancer mechanismsOsama M Alian, Asfar S Azmi, Ramzi M Mohammad
The American Journal of Pathology|December 19, 2018
miRNA and Gene Expression in Pancreatic Ductal AdenocarcinomaAnteneh A Tesfaye, Asfar S Azmi, Philip A Philip
F1000Research|December 24, 2013
Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer propertyAsfar S Azmi, Fazlul H Sarkar, S M Hadi
Recent Patents on Cardiovascular Drug Discovery|February 4, 2012
A(3) adenosine receptor: a plausible therapeutic target for cardio-protection in diabetesShamama Nishat, Hiba Shabir, Asfar S Azmi, et al.
Current Pharmaceutical Design|March 28, 2013
Understanding XPO1 target networks using systems biology and mathematical modelingIrfana Muqbil, Michael Kauffman, Sharon Shacham, et al.
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Oncotargets and Therapy|February 14, 2014
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancerMarwan Al-Hajeili, Asfar S Azmi, Minsig Choi
Cancers|May 9, 2018
Nuclear Export Inhibition for Pancreatic Cancer TherapyIrfana Muqbil, Asfar S Azmi, Ramzi M Mohammad
Drug Discovery Today|June 23, 2020
Exportin 1 inhibition as antiviral therapyMd Hafiz Uddin, Jeffrey A Zonder, Asfar S Azmi
Nature Reviews. Clinical Oncology|November 11, 2020
The nuclear export protein XPO1 - from biology to targeted therapyAsfar S Azmi, Mohammed H Uddin, Ramzi M Mohammad
Frontiers in Oncology|December 19, 2022
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Sahar F Bannoura, Husain Yar Khan, Asfar S Azmi
Clinical and Translational Medicine|February 2, 2013
Network insights on oxaliplatin anti-cancer mechanismsOsama M Alian, Asfar S Azmi, Ramzi M Mohammad
The American Journal of Pathology|December 19, 2018
miRNA and Gene Expression in Pancreatic Ductal AdenocarcinomaAnteneh A Tesfaye, Asfar S Azmi, Philip A Philip
F1000Research|December 24, 2013
Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer propertyAsfar S Azmi, Fazlul H Sarkar, S M Hadi
Recent Patents on Cardiovascular Drug Discovery|February 4, 2012
A(3) adenosine receptor: a plausible therapeutic target for cardio-protection in diabetesShamama Nishat, Hiba Shabir, Asfar S Azmi, et al.
Current Pharmaceutical Design|March 28, 2013
Understanding XPO1 target networks using systems biology and mathematical modelingIrfana Muqbil, Michael Kauffman, Sharon Shacham, et al.
Pageof 16